Three-drug combination for relapsed or refractory large B-cell lymphoma
Part of Cancer clinical trials.
This trial tests a combination of three drugs (golcadomide, poseltinib, and rituximab) for people with a type of lymphoma that has returned or not responded to previous treatment. The goal is to see if this combination is safe and effective for those who cannot have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years of age or older.
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma or a similar aggressive large B-cell lymphoma.
- Your lymphoma must have come back or not responded after at least one prior treatment that included an anthracycline (a common type of chemotherapy).
- You must NOT be eligible for a stem cell transplant.
- You must have at least one tumor that can be measured on a scan.
- You need to be in generally good health, with acceptable blood counts, liver, kidney, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of four drugs—sonrotoclax, glofitamab, gemcitabine, and oxaliplatin—in people with large B-cell lymphoma that has come back or not responded to earlier treatment. The goal is to see if this combination can shrink or control the lymphoma.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
This trial tests a new combination of three drugs for people recently diagnosed with a type of lymphoma called large B-cell lymphoma. The goal is to see if this combination is safe and effective, and it might offer a new treatment option.
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hear when a new Large B-Cell Lymphoma (LBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.